Drugs / Donor-derived ex-vivo expanded EBV Tscm CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05688241 | Nov 2026 → Dec 2031 expected | lymphoma, post-transplant lymphoproliferative disease | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived ex-vivo expanded EBV Tscm CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05688241 ↗ |
| Action | Deplete | “effective tumor cell killing” NCT05688241 ↗ |
| Modality | Cell therapy | “EBV-specific T-cell therapy” NCT05688241 ↗ |
| Route | Other | “infused” NCT05688241 ↗ |